Blog

3 Takeaways from the World Vaccine Congress 2018

BIO 2018: The Emergence of Gene & Cell Therapy

BioInnovation on Parade: Philly Stands Proud for BIO 2019!

Controlling Impurities in Cell Culture Media

ECI Conference 2019: The Latest Innovations and Trends in Cell & Gene Therapy

Evolving Challenges in Closed-System Biomanufacturing

Explore the Latest Developments in T-reg Research and Clinical Application

Exploring the Latest Research and Opportunities in T-reg Therapy

Happy Holidays from the InVitria Team!

High-Performance Production of Viral Vectors for Cell and Gene Therapy Using OptiPEAK HEK293t Complete Media

InVitria at the American Association of Immunologists 2018 Conference

InVitria Expands Operations to Anschutz Medical Campus in the Denver Metro Area

InVitria’s Top Insights from ISCT 2018 – Montreal

Join InVitria at ECI 2019

Join InVitria at Phacilitate 2019

Optibumin vs Traditional Albumin: Comparing Performance in Cell Wash Applications

Recombinant Albumin for Stabilization of Live-Attenuated Viral Vaccines

Recombinant Virus Platforms are Out in Front in the Race to Develop Vaccines Against SARS-CoV-2 and COVID-19 Disease

SARS-CoV2 and Influenza – Double Threat

Scaling Innovation: How DiscGenics and InVitria are Leading the Future of Cell Therapy

Solving the Vaccine Supply Challenge

Universal Vaccine Against Seasonal Influenza Steps Closer to Reality with the Results of FluGen Phase 2 Clinical Trial